Table 2. Cost of cardiovascular (CV) medications used for selected CV risk management strategies, Seychelles, 2004.
| Management strategy and medication | Cost (2004 US$) per daya |
|
|---|---|---|
| Seychelles | India | |
| Single-risk-factor | ||
| BP ≥ 140/90 mmHg | ||
| Lisinopril (ACEI) | 0.38 | 0.15 |
| Atenolol (BB) | 0.04 | 0.04 |
| Hydrochlorothiazide (D) | 0.01 | 0.03 |
| Amlodipine (CCB) | 0.10 | 0.04 |
| TSC ≥ 6.2 mmol/l | ||
| Atorvastatin | 1.46 | 0.12 |
| BP ≥ 140/90 mmHg or TSC ≥ 6.2 mmol/l | ||
| Antihypertensives and atorvastatin | 1.16 | 0.18 |
| Total CV risk | ||
| CV risk ≥ 10% | ||
| Polypillb | – | 0.26 |
| CV risk ≥ 20% | ||
| Polypillb | – | 0.26 |
| CV risk ≥ 20% or BP ≥ 160/100 mmHg or SC ≥ 8.0 mmol/l | ||
| Polypillb | – | 0.26 |
ACEI, angiotensin-converting enzyme inhibitor; BB, β-blocker; BP, blood pressure; CCB, calcium channel blocker; D, diuretic; TSC, total serum cholesterol; US$, United States dollars.
a The costs of medications in India and Seychelles were obtained from references Gupta et al.27 and Bovet et al.,20 respectively.
b Composed of aspirin, a statin, a diuretic and an ACEI.